Market sentiment is shifting from AI hardware euphoria to capex skepticism, highlighted by concerns over Nvidia's circular financing of hyperscalers. China's DUV mass production and CXMT's massive IPO are pressuring Western semis. Meanwhile, capital is rotating into software and capex-light tech.
Investors are increasingly scrutinizing massive AI capital expenditures lacking immediate ROI. Nvidia's reported $250B-$750B financing guarantees for OpenAI and others are raising red flags about 'circular financing' artificially inflating demand. This is driving a rotation out of hardware into software and capex-light tech.
Reports that China has begun mass-producing domestic DUV lithography tools triggered a sharp sell-off in Western semiconductor equipment stocks. Concurrently, Chinese memory maker CXMT surged 466% in its IPO, signaling aggressive capacity expansion that could commoditize the DRAM market.
Despite Houthi drone strikes on Saudi oil infrastructure, ongoing disruptions in the Strait of Hormuz, and the U.S. Strategic Petroleum Reserve hitting 1983 lows, oil prices have declined. Traders note extreme market complacency compared to 2022 supply shock reactions.
Pentosh1 disclosed accumulating tactical long positions in EWY, AAOI, NBIS, and SNDK after a six-week wait, citing deep pullbacks from highs.
Caesar Capital increased its position in AAOI at $95.55, lowering its average cost basis to $107.89 and signaling continued high conviction.
Mark Minervini initiated a short position in SPY as a partial hedge against his existing long portfolio, citing historical seasonal headwinds for August-September.
MicroStrategy raised $544.5 million via ATM share sales but paused Bitcoin purchases, opting to build its USD reserves instead.
Steve Eisman sold his long-term stake in Alphabet, warning that AI capital expenditures may fail to deliver expected returns and face margin erosion from cheaper models.
Trader seedy19tron disclosed a short position in SLS, arguing the upcoming trial is statistically powered with zero margin for error and relies on a historically failed vaccine mechanism.